The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase 2 trial of plinabulin (NPI-2358) plus docetaxel in patients with advanced non-small cell lung cancer (NSCLC).
Rebecca Suk Heist
Research Funding - Nereus Pharmaceuticals
Osvaldo Rudy Aren
Research Funding - Nereus Pharmaceuticals
Alain C. Mita
Research Funding - Nereus Pharmaceuticals
Jonathan Polikoff
Research Funding - Nereus Pharmaceuticals
Lyudmila Bazhenova
Research Funding - Nereus Pharmaceuticals
G Kenneth Lloyd
Consultant or Advisory Role - BeyondSpring Pharmaceuticals; Nereus Pharmaceuticals
Stock Ownership - Nereus Pharmaceuticals
William Mikrut
Consultant or Advisory Role - BeyondSpring Pharmaceuticals
Steven D. Reich
Consultant or Advisory Role - BeyondSpring Pharmaceuticals; Nereus Pharmaceuticals
Matthew A. Spear
Stock Ownership - Nereus Pharmaceuticals
Lan Huang
Employment or Leadership Position - Pharmaceuticals
Stock Ownership - BeyondSpring Pharmaceuticals